Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma

被引:20
作者
Oecal, Osman [1 ]
Ingrisch, Michael [1 ]
Uemuetlue, Muzaffer Reha [1 ]
Peynircioglu, Bora [2 ]
Loewe, Christian [3 ]
van Delden, Otto [4 ]
Vandecaveye, Vincent [5 ]
Gebauer, Bernhard [6 ]
Zech, Christoph J. [7 ]
Sengel, Christian [8 ]
Bargellini, Irene [9 ]
Iezzi, Roberto [10 ]
Benito, Alberto [11 ]
Pech, Maciej [12 ,13 ]
Malfertheiner, Peter [14 ]
Ricke, Jens [1 ]
Seidensticker, Max [1 ]
机构
[1] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Radiol, Munich, Germany
[2] Hacettepe Univ, Dept Radiol, Ankara, Turkey
[3] Med Univ Vienna, Dept Bioimaging & Image Guided Therapy, Sect Cardiovasc & Intervent Radiol, Vienna, Austria
[4] Univ Amsterdam, Acad Med Ctr, Dept Radiol & Nucl Med, Amsterdam, Netherlands
[5] Univ Hosp Leuven, Dept Radiol, Leuven, Belgium
[6] Charite Univ Med Berlin, Dept Radiol, Berlin, Germany
[7] Univ Basel, Univ Hosp Basel, Radiol & Nucl Med, Basel, Switzerland
[8] Grenoble Univ Hosp, Radiol Dept, La Tronche, France
[9] Univ Hosp Pisa, Dept Vasc & Intervent Radiol, Pisa, Italy
[10] Fdn Policlin Univ A Gemelli IRCCS, UOC Radiol, Dipartimento Diagnost Immagini Radioterapia Oncol, Rome, Italy
[11] Clin Univ Navarra, Dept Radiol, Abdominal Radiol Unit, Pamplona, Spain
[12] Univ Magdeburg, Dept Radiol, Magdeburg, Germany
[13] Univ Magdeburg, Dept Nucl Med, Magdeburg, Germany
[14] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Med 2, Munich, Germany
关键词
INTERNAL RADIATION-THERAPY; ENHANCED MR-IMAGES; MICROVASCULAR INVASION; SORAFENIB; RECURRENCE; SARAH;
D O I
10.1038/s41416-021-01577-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims To investigate the prognostic value of baseline imaging features for overall survival (OS) and liver decompensation (LD) in patients with hepatocellular carcinoma (HCC). Design Patients with advanced HCC from the SORAMIC trial were evaluated in this post hoc analysis. Several radiological imaging features were collected from baseline computed tomography (CT) and magnetic resonance imaging (MRI) imaging, besides clinical values. The prognostic value of these features for OS and LD (grade 2 bilirubin increase) was quantified with univariate Cox proportional hazard models and multivariate Least Absolute Shrinkage and Selection Operator (LASSO) regression. Results Three hundred and seventy-six patients were included in this study. The treatment arm was not correlated with OS. LASSO showed satellite lesions, atypical HCC, peritumoral arterial enhancement, larger tumour size, higher albumin-bilirubin (ALBI) score, liver-spleen ratio <1.5, ascites, pleural effusion and higher bilirubin values were predictors of worse OS, and higher relative liver enhancement, smooth margin and capsule were associated with better OS. LASSO analysis for LD showed satellite lesions, peritumoral hypointensity in hepatobiliary phase, high ALBI score, higher bilirubin values and ascites were predictors of LD, while randomisation to sorafenib arm was associated with lower LD. Conclusions Imaging features showing aggressive tumour biology and poor liver function, in addition to clinical parameters, can serve as imaging biomarkers for OS and LD in patients receiving sorafenib and selective internal radiation therapy for HCC.
引用
收藏
页码:211 / 218
页数:8
相关论文
共 37 条
  • [1] Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial
    Alunni-Fabbroni, Marianna
    Roensch, Kerstin
    Huber, Thomas
    Cyran, Clemens C.
    Seidensticker, Max
    Mayerle, Julia
    Pech, Maciej
    Basu, Bristi
    Verslype, Chris
    Benckert, Julia
    Malfertheiner, Peter
    Ricke, Jens
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (01)
  • [2] Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion
    An, Jihyun
    Lee, Kwang Sun
    Kim, Kang Mo
    Park, Do Hyun
    Lee, Sang Soo
    Lee, Danbi
    Shim, Ju Hyun
    Lim, Young-Suk
    Lee, Han Chu
    Chung, Young-Hwa
    Lee, Yung Sang
    [J]. CLINICAL AND MOLECULAR HEPATOLOGY, 2017, 23 (02) : 160 - 169
  • [3] Ariizumi Shun-Ichi, 2019, Anticancer Res, V39, P4219, DOI 10.21873/anticanres.13583
  • [4] Radioembolization-induced liver disease: a systematic review
    Braat, Manon N. G. J. A.
    van Erpecum, Karel J.
    Zonnenberg, Bernard A.
    van den Bosch, Maurice A. J.
    Lam, Marnix G. E. H.
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2017, 29 (02) : 144 - 152
  • [5] Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
    Cheng, Ann-Lii
    Kang, Yoon-Koo
    Chen, Zhendong
    Tsao, Chao-Jung
    Qin, Shukui
    Kim, Jun Suk
    Luo, Rongcheng
    Feng, Jifeng
    Ye, Shenglong
    Yang, Tsai-Sheng
    Xu, Jianming
    Sun, Yan
    Liang, Houjie
    Liu, Jiwei
    Wang, Jiejun
    Tak, Won Young
    Pan, Hongming
    Burock, Karin
    Zou, Jessie
    Voliotis, Dimitris
    Guan, Zhongzhen
    [J]. LANCET ONCOLOGY, 2009, 10 (01) : 25 - 34
  • [6] Hepatocellular Carcinoma: Imaging Patterns on Gadoxetic Acid-enhanced MR Images and Their Value as an Imaging Biomarker
    Choi, Jin Woo
    Lee, Jeong Min
    Kim, Soo Jin
    Yoon, Jeong-Hee
    Baek, Jee Hyun
    Han, Joon Koo
    Choi, Byung Ihn
    [J]. RADIOLOGY, 2013, 267 (03) : 776 - 786
  • [7] SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
    Chow, Pierce K. H.
    Gandhi, Mihir
    Tan, Say-Beng
    Khin, Maung Win
    Khasbazar, Ariunaa
    Ong, Janus
    Choo, Su Pin
    Cheow, Peng Chung
    Chotipanich, Chanisa
    Lim, Kieron
    Lesmana, Laurentius A.
    Manuaba, Tjakra W.
    Yoong, Boon Koon
    Raj, Aloysius
    Law, Chiong Soon
    Cua, Ian H. Y.
    Lobo, Rolley R.
    Teh, Catherine S. C.
    Kim, Yun Hwan
    Jong, Yun Won
    Han, Ho-Seong
    Bae, Si-Hyun
    Yoon, Hyun-Ki
    Lee, Rheun-Chuan
    Hung, Chien-Fu
    Peng, Cheng-Yuan
    Liang, Po-Chin
    Bartlett, Adam
    Kok, Kenneth Y. Y.
    Thng, Choon-Hua
    Low, Albert Su-Chong
    Goh, Anthony S. W.
    Tay, Kiang Hiong
    Lo, Richard H. G.
    Goh, Brian K. P.
    Ng, David C. E.
    Lekurwale, Ganesh
    Liew, Wei Ming
    Gebski, Val
    Mak, Kenneth S. W.
    Soo, Khee Chee
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (19) : 1913 - +
  • [8] Diffusion-weighted imaging for identifying patients at high risk of tumor recurrence following liver transplantation
    Chuang, Yi-Hsuan
    Ou, Hsin-You
    Yu, Chun-Yen
    Chen, Chao-Long
    Weng, Ching-Chun
    Tsang, Leo Leung-Chit
    Hsu, Hsien-Wen
    Lim, Wei-Xiong
    Huang, Tung-Liang
    Cheng, Yu-Fan
    [J]. CANCER IMAGING, 2019, 19 (01)
  • [9] Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Kim, Tae-You
    Kudo, Masatoshi
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed O.
    Li, Daneng
    Verret, Wendy
    Xu, Derek-Zhen
    Hernandez, Sairy
    Liu, Juan
    Huang, Chen
    Mulla, Sohail
    Wang, Yulei
    Lim, Ho Yeong
    Zhu, Andrew X.
    Cheng, Ann-Lii
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) : 1894 - 1905
  • [10] Prediction of hepatocellular carcinoma response to 90Yttrium radioembolization using volumetric ADC histogram quantification: preliminary results
    Gordic, Sonja
    Wagner, Mathilde
    Zanato, Riccardo
    Hectors, Stefanie
    Besa, Cecilia
    Kihira, Shingo
    Kim, Edward
    Taouli, Bachir
    [J]. CANCER IMAGING, 2019, 19 (1):